Poll results: How comfortable are you with including biosimilars in your treatment plans?

Poll

See the results from our recent poll!

Optometry Times asked our audience, "How comfortable are you with including biosimilars in your treatment plans?" and the results are in!

The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 15 to Feb. 22, 2023.

10 ODs responded:

- 4 said, "Very excited to begin embracing biosimilars"

- 4 said, "Feeling comfortable exploring biosimilar options, though cautiously"

- 0 said, "Still hesitant, I need to learn more about biosimilars"

- 2 said, "With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans"

To learn more about biosimilars for AMD, check out Euin Cheong, OD's piece on "Introduction to biosimilars for AMD."

Recent Videos
Drs Erin Draper and Chris Cuk outline the important role optometrists have in spotting neurodegenerative disease in patients
Mohammad Rafieetary, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
© 2024 MJH Life Sciences

All rights reserved.